These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26858375)

  • 21. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2009 Dec; 124 Suppl 5():S459-65. PubMed ID: 19948577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The U.S. vaccine supply.
    Hinman AR
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15758020
    [No Abstract]   [Full Text] [Related]  

  • 24. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1325-31. PubMed ID: 19047253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing government-operated vaccine programs: an industry perspective.
    Paradiso PR
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S118-20. PubMed ID: 16447132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States.
    Shen AK; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fragility of the U.S. vaccine supply.
    Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB
    N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064
    [No Abstract]   [Full Text] [Related]  

  • 31. The U.S. vaccine supply.
    Schwartz HK
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
    [No Abstract]   [Full Text] [Related]  

  • 32. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wyeth responds to criticism.
    Stiles GM
    Md Med; 2005; 6(4):5, 7-8; author reply 8. PubMed ID: 16454430
    [No Abstract]   [Full Text] [Related]  

  • 34. Improving vaccine supply and development: who needs what?
    Pauly MV
    Health Aff (Millwood); 2005; 24(3):680-9. PubMed ID: 15886159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil.
    Mahoney RT; Francis DP; Frazatti-Gallina NM; Precioso AR; Raw I; Watler P; Whitehead P; Whitehead SS
    Vaccine; 2012 Jul; 30(32):4892-6. PubMed ID: 22406455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases.
    Kirchheimer B
    Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833
    [No Abstract]   [Full Text] [Related]  

  • 37. Economic and technological drivers of generic sterile injectable drug shortages.
    Woodcock J; Wosinska M
    Clin Pharmacol Ther; 2013 Feb; 93(2):170-6. PubMed ID: 23337525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on vaccine liability in the United States: presentation at the National Vaccine Program Office Workshop on strengthening the supply of routinely recommended vaccines in the United States, 12 February 2002.
    Evans G
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S130-7. PubMed ID: 16447135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of shortages of opioid analgesics in the US: Are the characteristics of the drug company the missing puzzle piece?
    Rodriguez-Monguio R; Naveed M; Seoane-Vazquez E
    PLoS One; 2021; 16(3):e0249274. PubMed ID: 33788898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lessons learned from the 2007 to 2009 Haemophilus influenzae type B vaccine shortage: implications for future vaccine shortages and public health preparedness.
    Chamberlain AT; Wells K; Seib K; Kudis A; Hannan C; Orenstein WA; Whitney EA; Hinman AR; Buehler JW; Omer SB; Berkelman RL
    J Public Health Manag Pract; 2012; 18(3):E9-E16. PubMed ID: 22473128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.